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Abstract
Background: Pancreatic cancer remains one of the most difficult cancers to treat with the poorest prognosis. The
key to improving survival rates in this disease is early detection and monitoring of disseminated and residual disease.
However, this is hindered due to lack reliable diagnostic and predictive markers which mean that the majority of
patients succumb to their condition within a few months.
Methods: We present a pilot study of the detection circulating free DNA (cfDNA) combined with tumor specific
mutation detection by digital PCR as a novel minimally invasive biomarker in pancreatic ductal adenocarcinoma
(PDAC). This was compared to the detection of CTC by the CellSearch® system and a novel CTC enrichment strategy
based on CD45 positive cell depletion. The aim of the study was to assess tumor specific DNA detection in plasma
and CTC detection as prognostic markers in PDAC.
Results: We detected KRAS mutant cfDNA in 26 % of patients of all stages and this correlated strongly with Overall
Survival (OS), 60 days (95 % CI: 19–317) for KRAS mutation positive vs 772 days for KRAS mutation negative (95 % CI:
416–1127). Although, the presence of CTC detected by the CellSearch® system did correlate significantly with OS,
88 days (95 % CI: 27–206) CTC positive vs 393 days CTC negative (95 % CI: 284–501), CTC were detected in only 20 %
of patients, the majority of which had metastatic disease, whereas KRAS mutant cfDNA was detected in patients with
both resectable and advanced disease.
Conclusions: Tumor specific cfDNA detection and CTC detection are promising markers for the management of
patients with PDAC, although there is a need to validate these results in a larger patient cohort and optimize the
detection of CTC in PDAC by applying the appropriate markers for their detection.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is the most
common cancer affecting the exocrine pancreas. In
Europe there are 60,139 new diagnoses and 64,801
deaths very year [1]. The prognosis of patients is dismal
with a 5 year survival rate of around 5 % as the majority
of patients diagnosed with PDAC present with an ad-
vanced disease and distant metastasis. Surgical resection
of the primary tumor is the only hope for a cure but un-
fortunately this is only possible in around 15–20 % of
patients.
There have been considerable improvements in long-
term survival following PDAC resection over last few
decades with 5-year survival rates of approximately 27 %
[2], however, 80 % of patients relapse within months
after an attempt at curative surgery [3]. There are several
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prognostic factors and predictors of relapse such as
tumor aneuploidy, positive lymph nodes, tumor size,
poor histological tumor differentiation and positive re-
section margins but there is a need for additional accur-
ate and reliable markers for effective monitoring of
disease evolution with regard to disease dissemination in
localized tumors and residual disease after treatment in
advanced patients.
The most commonly used tumor biomarker in PDAC
is carbohydrate antigen 19–9 (CA 19–9), the sensitivity
is around 79 % and specificity 82 %. However, CA19-9
levels increase in other non-malignant pancreatic disor-
ders such as acute pancreatitis and other gastrointestinal
malignancies [4, 5]. Circulating branched-chain amino
acids have also been proposed as a novel biomarker
appearing 2–5 years before diagnosis [6]. However, there
is still a need for new diagnostic and predictive bio-
markers that complement imaging techniques used in
patient follow-up in order to achieve a more effective
management of these patients and improve survival.
The presence of circulating tumor cells (CTC) in
peripheral blood has been associated with a reduced
progression free survival (PFS) and overall survival (OS)
in some cancer types and may be useful as an early indi-
cator of tumor spread, as invasive but localized tumors
may shed CTC into the blood stream before a metastasis
is established. The CellSearch® system enumerates CTC
based on the expression of epithelial markers and has
been used extensively in predicting prognosis and re-
sponse to treatment in breast, colon, lung and prostate
cancers [7–10] although there are few studies of CTC as
a biomarker in PDAC. 45 % of patients with stage IV
disease tested positive for CTC in one study whereas
5 % of patients with a locally advanced disease were
CTC positive in another study using the CellSearch®
system [11, 12]. A comparative study in metastatic or
inoperable pancreatic cancer detected CTC in 40 % of
patients using the CellSearch® system as compared to
93 % by ISET (Isolation by Size of Tumor cells), on the
whole more CTCS were detected by ISET than by Cell-
Search®, mean 26 versus 2 CTCs/7.5 ml of blood (range
0–240 versus 0–15) [13]. The limitation of the cell
search system is that circulating tumor cells that do not
express the marker EpCAM and/or Cytokeratins 8, 18
and 19 will not be detected by the system. Other CTC de-
tection systems include the isoflux, ImageStreamXsystems,
however, these have not been validated in the context of
pancreatic cancer.
Nucleic acids are released and circulate in the peripheral
due to apoptosis and necrosis of cells. During tumorigen-
esis there is an increase in cell turnover and thus more cell
necrosis and apoptosis which is released into the blood
stream and leads to an accumulation of cfDNA, thus can-
cer patients tend to have more cfDNA than non-cancer
patients [14]. Thus, cfDNA has been exploited as a cancer
biomarker, high plasma cfDNA content is associated with
poor survival in patients with lung adenocarcinoma,
similarly a study in colorectal cancer has shown that the
concentration of cfDNA correlates strongly with clinical
outcome [15, 16]. One drawback of this approach is that
cfDNA content may increase in non-cancer states such as
benign tumors and inflammatory diseases thus DNA con-
centration alone is not an adequate marker to distinguish
between cancer and non-cancer states. Thus it would be
ideal to use this in combination with tumor specific DNA
mutation detection, such as mutant KRAS, which is the
most common genetic alteration found in PDAC occur-
ring in approximately 90 % of tumors [17].
This is an exploratory study of tumor specific mutation
detection in cfDNA in patients diagnosed with PDAC. In
addition, we evaluate the quantification of cfDNA in
plasma, tumor specific mutation detection in plasma as
well as CTC detection in peripheral blood as prognostic
biomarkers in PDAC using overall survival analysis.
Methods
Patients
Patients were recruited via the Medical Oncology and
Surgery Departments at the Ramón y Cajal hospital,
Madrid, Spain between October 2009 and May 2014.
The study was approved by the clinical investigation eth-
ics committee of the Ramón y Cajal University Hospital
and all participants signed the associated informed
consent form. The study included a total of 45 patients
with histological or cytological confirmed PDAC diag-
nosed at different disease stages (resectable, locally
advanced and metastatic disease). The patients were di-
vided into 2 cohorts; this included (1) 31 patients with
cfDNA concentration and KRAS mutation detection
data and (2) 35 patients with CTC data. 21 patients had
both sets of data. When possible, samples were taken
prior to starting treatment, either surgery or chemother-
apy, although 7 patients had previously received gemci-
tabine chemotherapy before the sample was taken.
cfDNA detection and quantification by digital PCR
cfDNA was extracted from 1 ml of plasma using the
QIAamp Circulating nucleic acid kit (Qiagen), DNA was
isolated in a final volume of 50 μl. The total DNA con-
centration in plasma was estimated by determination of
the number of copies of the RNaseP (RPP30) gene, as
this gene is rarely affected by mutations or copy number
alterations. The number of copies of the RNaseP gene
was determined by ddPCR amplification using the
QX200™ Droplet Digital™ PCR System (BioRad) using a
specific PrimePCR copy number assay (BioRad, RPP30
dHsaCP1000485) according to the manufacturer’s
instructions. 1 μl of isolated cfDNA corresponding to
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20 μl of plasma was used as a template for each PCR
and reactions were performed in duplicate with non-
template negative controls.
Absolute quantities of RNaseP DNA copies were de-
termined using the QuantaSoft software supplied by the
manufacturer. Briefly, a fluorescence intensity threshold
of 3000 was set and all droplets above this threshold
were scored as positive. Each positive droplet corre-
sponded to a single copy of the RNaseP gene. cfDNA
concentration was expressed as the total number of
copies of RNaseP in 20 μl of plasma.
Tumor specific mutation detection in cfDNA by digital PCR
Information on the frequency of mutations in KRAS in pri-
mary PDAC was retrieved from the COSMIC database
[17]. The QX200TM Droplet Digital PCR System (Biorad)
and the PrimePCR KRAS mutant assays (Biorad, dHsaCP
2000001 (G12D), dHsaCP2000009 (G12R), dHsaCP
2000005 (G12V),) and corresponding WT assays (dHsa
CP2000002 (G12D), dHsaCP2000006 (G12V), dHsaCP
2000010 (G12R)) were used to detect the following KRAS
mutations in cfDNA: G12D, G12R and G12V. 1 μl of iso-
lated cfDNA was used as a template for each PCR. Dupli-
cates samples were analyzed as well as the corresponding
mutation positive control DNA for the mutations tested.
The positive control DNA for each assay was also used as
a negative control for other assays in order to determine
the level of non-specific amplification. Additional non-
template negative controls were also included.
Following PCR amplification, absolute quantities of mu-
tant and WT DNA copies were determined using the
QuantaSoft software as previously described. Briefly, the
system uses a 2 color detection system for the WT (FAM)
and Mutant (HEX) alleles to count the number of droplets
positive for each fluorophore. We considered samples as
positive for mutant KRAS when at least 3 positive HEX
droplets were identified above the threshold level.
KRAS mutation detection by ddPCR in plasma spiked with
KRAS mutant DNA
1 ml of plasma from a healthy control was spiked with
250 ng, 100 ng, 50 ng and 25 ng of DNA from the pan-
creas cancer cell line, SUIT-2, that harbors the G12D
KRAS mutation. cfDNA was extracted from these sam-
ples as well 1 ml of un-spiked plasma and G12D KRAS
mutation detection by ddPCR was performed as previ-
ously described.
Genomic DNA extraction and KRAS sequencing in
primary tumors
Paraffin embedded tissue from primary tumors was
assessed by an experienced pathologist and an area cor-
responding to tumor was selected for DNA extraction.
The tumor content was macro dissected by tissue punch.
Genomic DNA was extracted from 12 paraffin embedded
primary tumor tissue using the Qiagen DNeasy Blood and
Tissue kit and exon 2 and 3 of the KRAS gene was ampli-
fied using the following primers KRAS exon 2 fwd 5′
ACACGTCTGCAGTCAACTGG-3′ KRAS exon 2 rev
5′-TAACTTGAAACCCAAGGTAC-3, KRAS exon 3 fwd
5′-GCACTGTAATAATCCAGACT-3 KRAS exon 3 rev
5′-CATGGCATTAGCAAAGACTC-3. The products were
sequenced by Sanger sequencing using the Big Dye®
Terminator v3.1 cycle sequencing kit (ABI) according to
the manufacturer’s instructions in order to verify the pres-
ence of a KRAS mutation.
CTC determination by CellSearch®
Briefly, 7.5 ml of blood was mixed with sample buffer
and centrifuged before loading into the CellSearch®
(Janssen) instrument for subsequent automated process-
ing. The CellSearch® system contains a ferro fluid-based
capture reagent targeting the EpCAM antigen of CTC and
immunofluorescent reagents targeting the intracellular
protein cytokeratin (epithelial cells), DAPI (nucleus) and
CD45 (leukocytes) for the identification and enumeration
of CTC. The Celltracks Analyzer II® System scans samples
and identifies events where cytokeratin and DAPI fluores-
cence are co-located. An event is classified as a tumor cell
when complying with the following criteria; (1) Morph-
ology: a round or oval intact cell with a minimum size of 4
microns (2) EpCAM positive, cytokeratin positive, DAPI
positive and CD45 negative (3) At least 50 % of the nucleus
must be visible inside the cytoplasm. A CellSearch® Circu-
lating Tumor Cell Control was analyzed in each sample
run which checks the overall system performance, includ-
ing the instrument, reagents and operator technique.
7.5 ml of peripheral blood was spiked with 750 cells of
the human pancreatic cancer cell lines AsPc-1 and
PaTu899S to obtain 100 cells per ml of blood; these
acted as pancreatic cancer tumor cell positive controls
and were processed as described previously. CTC calling
was performed by trained personnel and verified by an
independent expert. According to the manufacturer, the
mean CTC count in healthy individuals is 0.1 (N= 145,
SD = 0.2) and 0.1 (N= 99, SD = 0.4) in patients with
non-malignant disease. We classified a sample as posi-
tive when 1 CTC was detected.
Enrichment of CTC by CD45 positive cell depletion in
peripheral blood
4 ml of blood was used to isolate and enrich circulating
tumor cells. Red blood cells were lysed using a hypotonic
solution of ammonium chloride. Magnetic Activated Cell
Sorting (MACS) was used to remove haematopoietic cells
that express the cell surface marker CD45 as described by
the manufacturer. Briefly, cells were counted after red
blood cell lysis and cells were resuspended in 80 μl of
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MACS buffer (PBS + 0.5 % BSA + 2 mM EDTA) with
20 μl of magnetically labelled CD45 antibody per 1 million
cells. After incubation at 4 °C for 15 min the cells were
washed twice in MACS buffer and CD45 positive and
negative cells were separated using MACS ferromagnetic
columns and washed in PBS before DNA extraction.
Genomic DNA extraction and KRAS sequencing in CD45
positive cell depleted blood
DNA was extracted from 9 CD45 negative isolated cell
population specimens using the Qiagen DNeasy Blood
and Tissue kit and exon 2 and 3 of the KRAS gene were
PCR amplified and sequenced as previously described.
Statistical analysis
Statistical Analysis was performed using R [18] and SPSS
[19]. Differences in age for the patient cohorts with
available data for CTC determination and KRAS muta-
tion in cfDNA were assessed with the non parametric
Mann–Whitney test. The Fisher exact test was applied
for the categorical variables such as sex and stage. The
Mann–Whitney was used to assess the differences in
concentration of cfDNA across the 3 disease stage
groups (resectable, locally advanced and metastatic), as
well as the assessment of differences in cfDNA concen-
tration according to KRAS mutation status. The Pearson
correlation was applied to determine the correlation be-
tween KRAS G12D DNA spike in concentration and the
number of G12D copies detected by ddPCR. Survival ana-
lysis with regard to CTC and KRAS mutation detection in
cfDNA was assessed in three ways. First, a univariate
analysis was performed using the Kaplan Meier estimate
of survival to compare CTC or mutant KRAS positive vs
negative patients with the Mantel-Haenszel test. Second a
Cox regression was fitted that included sex and age as
confounders. Finally a Weibull regression analysis was
performed using the parameters sex and age.
Results
Patient characteristics
The characteristics of the 45 patients included in the
study are shown in Table 1. 24 patients were male and
21 female, the median age at diagnosis was 68 years of
age (66 years of age for males and 69.5 years of age for
females). Patients were divided into 3 clinical groups:
(1) patients with a localized that are eligible for surgical
resection (R), (2) patients with a locally advanced dis-
ease but not eligible for surgery (LA), (3) patients
with stage IV metastatic disease (M). Tweenty-one
patients had both sets of data. Statistical analysis of
the cohorts of patients with cfDNA data, CTC data
or both data showed that they were equivalent popu-
lations in terms of sex and stage, although the cfDNA
only group had a younger age at diagnosis (Additional
file 1: Table S1).
Measurement of DNA concentration in plasma
The number of copies of the RNaseP gene was taken as
a measurement of total DNA concentration in plasma
samples. This information was available for 31 patients
(Table 1). The median number of copies of the RNaseP
gene in 20 μl of plasma was 93 (range 6–1663, 25 % per-
centile 55.5 and 75 % percentile 312.5). DNA concentra-
tion in plasma tended to increase with increasing disease
stage although this correlation did not reach statistical
significance (Fig. 1). There was no obvious correlation
with OS based only on DNA concentration in plasma.
Specificity of KRAS ddPCR mutation assays
The specificity of the G12D, G12R and G12V KRAS
mutation assays was tested by ddPCR amplification of
DNA samples harboring these 3 mutations. The re-
sults are shown in Additional file 2: Figure S1. There
was no non-specific amplification above the threshold
level with the G12D and G12R assays. However, there
was non-specific amplification of G12D mutant DNA
with the G12V assay.
KRAS mutation detection in spiked plasma by ddPCR
Plasma spiked with KRAS G12D mutant DNA and ana-
lyzed by ddPCR is shown in Additional file 3: Figure S2a.
The number of G12D mutant copies detected in each
spike in plasma is shown in Additional file 3: Figure S2b.
The correlation coefficient between the number of G12D
copies detected by ddPCR and the spike in concentration
was 0.99 (p < 0.01). The system detected KRAS G12D
mutant spike in DNA down to a concentration of 0.5 ng
which represented 37 mutant copies.
KRAS detection in cfDNA using digital PCR
KRAS mutation detection in cfDNA data for the muta-
tions G12D, G12V and G12R was available for 31 pa-
tients (Table 1). An example of KRAS G12D detection
in plasma DNA by ddPCR is shown in Fig. 2a with the
corresponding positive control G12D mutant DNA and
WT DNA, as well G12D mutant DNA spiked and non-
spiked plasma. 8/31 (26 %) patients were positive for a
KRAS mutation. Six patients had the G12D mutation
and 1 patient had the G12R and another had the G12V
mutation. This included 3 patients with a resectable dis-
ease, one with a locally advanced disease and 4 with
metastatic disease (Fig. 2b). Seven patients tested for a
KRAS mutation had previously received chemotherapy,
one was positive for a KRAS mutation and the
remaining patients were negative. The concentration of
DNA was significantly higher in plasma from patients
that tested positive for a mutation in KRAS as compared
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1 R YES YES 80 NEG G12D
2 R YES YES 43 NEG G12R
3 R YES YES 59 NEG
4 R NO YES YES YES 106 NEG NEG 0
5 R NO YES YES YES 97 NEG NEG 0 WT WT
6 R NO YES YES YES 185 POS G12D 0,21 POS 1 G12D
7 R NO YES NEG 0 WT
8 R NO YES NEG 0
9 R NO YES 86 POS G12D 0,1 WT WT
10 R NO YES YES YES 93 POS G12D 0,01 NEG 0 G12D
11 R NO YES YES YES 48 NEG NEG 0 G12S
12 R NO YES YES YES 1541 NEG NEG 0
13 R NO YES NEG 0
14 R NO YES NEG 0
15 LA NO YES 52 POS G12V 0,12
16 LA NO YES YES yes 6,4 NEG NEG 0
17 LA NO YES YES YES 66 NEG NEG 0 G12D
18 LA NO YES YES YES 1063 NEG NEG 0
19 LA NO YES NEG 0
20 LA YES YES 297 NEG
21 LA NO YES YES YES 700 NEG NEG 0
22 LA YES YES YES YES 38 NEG NEG 0
23 LA NO YES YES YES 111 NEG NEG 0
24 LA NO YES NEG 0
25 LA NO YES NEG 0 G12D
26 LA NO YES NEG 0
27 LA NO YES NEG 0
28 M NO YES 806 POS G12D 0,06
29 M NO YES YES YES 12,2 NEG NEG 0
30 M YES YES YES YES 1663 POS G12D 2,43 POS 5 WT
31 M NO YES YES YES 72 NEG NEG 0 WT
32 M NO YES YES YES 1095 POS G12R 0,02 POS 4 G12R
33 M NO YES NEG 0
34 M NO YES NEG 0
35 M NO YES POS 3
36 M NO YES 130 NEG
37 M NO YES 147 NEG G12D
38 M YES YES 87 NEG G12D
39 M NO YES YES YES 33 NEG NEG 0 WT
40 M NO YES YES YES 328 NEG NEG 0 G12D
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to those that tested negative (Fig. 2c). Patients that
tested positive for a KRAS mutation in plasma had a sig-
nificantly shorter overall survival than patients that
tested negative for a mutation (Fig. 2d), 60 days (95 %
CI:19–317) KRAS mutation positive vs 772 days for mu-
tation negative (95 % CI:416–1127) according to the
Kaplan Meier analysis (p = 0.001). However, due to the
small patient cohort we performed a more rigorous
statistical analysis of survival in order to confirm this
association. The cox regression model (which cor-
rected for the effects of age and sex of patients)
showed a significant difference in overall survival for
KRAS positive vs KRAS negative patients with a haz-
ard ratio of 12.2 (3.3-45.1, p = <0.001) (Additional file
4: Table S2 and Additional file 5: Figure S3). Finally
the Weibull regression analysis confirmed these re-
sults with a HR 12.2 (3.6-40.7, p = <0.001) (Additional
file 4: Table S2, Additional file 6: Fig. S4).
KRAS mutation detection in primary tumor tissue
Paraffin embedded primary tumor tissue was available
for 12 of the 31 patients tested for a KRAS mutation in
plasma. KRAS mutation detection is summarized in
Table 1. 5/12 primary tumors tested wildtype for KRAS
and 7/12 tested mutant (4 G12D, 1 G12R, 1 G12V, 1
G12S). KRAS mutation status in primary tissue was
available for 5 of the 8 patients that tested positive for
KRAS mutation in plasma. The same mutation was con-
firmed in 3 of these patients whilst the remaining 2
tumor samples tested WT for KRAS. With regard to
patients that tested negative for a KRAS mutation in
plasma, 4/7 of these patients tested positive for a muta-
tion in the primary tumor (2 G12D, 1 G12R, 1 G12S)
and the remaining tested wildtype. Of the 4 that tested
negative for a mutation in plasma and positive in the
primary tumor, 3 had previously received chemotherapy
before sample extraction.
CTC detection in PDAC patients
CTC data were available for 35 patients (Table 1). CTC
were detected in 7/35 (20 %) patients analyzed, this in-
cluded 6 patients with metastatic disease and 1 patient
with a resectable tumor (Fig. 3a). One patient with meta-
static disease had 13 CTC, one had 4, another had 5
CTC, one had 1 CTC and two had 3 CTC. The patient
with resectable disease had 1 CTC. No CTC were de-
tected in patients with a locally advanced disease. Two
patients with CTC determination data had previously re-
ceived chemotherapy, 1 patient had 5 CTC and the sec-
ond was negative for CTC. AsPc-1 and PaTu899S
pancreatic cancer cell lines were successfully detected by
the CellSearch system confirming that tumor cells of
pancreatic origin are detectable by this system (Fig. 3b).
CTC positive patients had a significantly shorter overall
survival (Fig. 3c), 88 days (95 % CI: 27–206) CTC
positive vs 393 days CTC negative (95 % CI: 284–501)
according to the Kaplan Meier analysis (p = 0.0108). A
Cox regression analysis with age and sex as cofounders
also showed a significant difference in overall survival
for CTC positive vs. CTC negative patients with a haz-
ard ratio of 3 (1.16–7.38, p 0.023) (Additional file 4:
Table S2 and Additional file 5: Figure S3). A Weibull
regression analysis confirmed these results with a HR
2.9(1.16–7.63, p = 0.025) (Additional file 4: Table S2,
Additional file 6: Fig. S4).
KRAS mutation detection in CD45 depleted blood samples
CD45 depleted blood samples were available for 9
patients. Exon 2 and 3 of KRAS was successfully PCR
amplified in all patients, this included 6 with CTC deter-
minations and 3 without. The G12D mutation was
Table 1 Characteristics of the PDAC patients included in the study (Continued)
41 M NO YES YES YES 602 POS G12D 0,81 POS 3
42 M NO YES YES YES 70 NEG NEG 0 WT
43 M NO YES YES YES 52 NEG POS 1 WT
44 M NO YES NEG 0
45 M NO YES POS 13
R Resectable, LA Locally Advanced, M Metastatic
Fig. 1 Correlation of total cfDNA concentration in plasma with
PDAC disease stage. *DNA concentration was estimated by the
number of copies of the RNaseP gene in 20 μl of cfDNA in plasma
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detected in four patients; two of these patients were
CTC negative by the CellSearch® system (Fig. 4). Three
patients positive for a KRAS G12D mutation in CD45
depleted blood were negative for a KRAS mutation in
plasma and another patient negative for a KRAS mutation
in depleted blood was positive for the G12D mutation in
plasma.
Mutant KRAS in cfDNA vs CTC detection
Data with regard to both CTC status and KRAS muta-
tion status in plasma was available for 21 patients. 4/5
patients positive for CTC were also positive for a KRAS
mutation in plasma. Another patient positive for a G12D
mutation in plasma was negative for CTC.
Discussion
We have demonstrated that tumor specific DNA can be
detected in plasma in patients with PDAC. In addition,
cfDNA concentration tends to increase with advanced
disease stages although this did not correlate with OS.
This may be due to the fact that cfDNA concentration is
influenced by tumor burden with may be variable among
patients due to differences in the clearing of cell debris
from the circulation [14].
ddPCR is a sensitive method for the detection of small
quantities of DNA and we have demonstrated that as
few as 0.5 ng of mutant DNA corresponding to 37 cop-
ies can be detected by this technique. However, we did
detect some non-specific amplification of G12D mutant
DNA with the G12V assay. The specific base affected in
these mutations is the same c.35G > A (G12D) and
c.35G > T (G12V), thus some non-specific amplification
may occur. However, it should be noted that there was
no non-specific amplification with WT DNA or G12R
mutant DNA (which is affected by a different base
c.34G > C).
G12D, G12V and G12R represent the most frequent
KRAS mutations found in sporadic PDAC primary tu-
mors with a frequency of 51 %, 29 % and 12 % of all
KRAS mutations respectively according to the COSMIC
Fig. 2 KRAS mutation detection in plasma cfDNA in PDAC cases. a. G12D KRAS mutation detection in plasma and genomic DNA by QX200™
Droplet Digital™ PCR. b. Frequency of mutant KRAS detection in plasma in PDAC. c. Correlation of cfDNA concentration and mutant KRAS
detection. *DNA concentration was estimated by the number of copies of the RNaseP gene in 20 μl of cfDNA in plasma. d. Kaplan Meier survival
analysis of KRAS mutation status in plasma cfDNA
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database [17]. However, there are other less frequently
occurring mutations such as G12C (2.8 %), G12S
(2.2 %), G12A (1.6 %), G13D (0.7 %), Q61H (0.7 % of all
primary tumors) that may also be present in cfDNA that
have not been tested here, thus the number of KRAS
positive patients is probably underestimated. Import-
antly, we demonstrate that tumor specific DNA can be
detected in PDAC plasma, even in patients with a resect-
able disease that supposedly has not yet metastasized or
released CTC into the peripheral blood.
Primary tissue from PDAC patients is limited due to
the fact that most patients present with advanced disease
and usually only fine-needle aspiration (FNA) biopsies
are available. However, we were able to obtain sufficient
DNA from 12 of the 31 patients tested for a KRAS mu-
tation in plasma in order to confirm the presence of the
same mutation in the primary tumor. The same KRAS
mutation found in plasma was also found in the primary
tumor in 3 of 5 patients with available tissue. The
remaining 2 patients tested WT for KRAS in the primary
Fig. 3 CTC detection whole blood in PDAC cases. a. Frequency of CTC in peripheral blood in PDAC. b. AsPc-1 and PaTu8988S detection in spiked
peripheral blood (100 cells/ml) using the CellSearch® system. c. Kaplan Meier survival analysis of CTC status in peripheral blood
Fig. 4 KRAS mutation detection in CD45 depleted blood. The KRAS G12D mutation was detected in 2 patients that tested negative for CTC by
the CellSearch® system
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tumor. This is most likely due to the fact that we per-
formed macro dissection of the tissue in order to obtain
tumor DNA and PDAC tumors contain a high propor-
tion of stromal tissue and thus we will ultimately have
contaminating non-tumor KRAS WT cells in the sam-
ple. Ideally micro-disection of PDAC tissue should be
performed to obtain a pure sample of tumor cells,
however this was not available in our facility. This
combined with the fact that PCR amplification
followed by Sanger sequencing is a low sensitivity
method for mutation detection, meaning that KRAS
mutation detection in these samples is challenging.
Of the 4 patients with mutant KRAS in the primary
tumor that were negative for a KRAS mutation in
plasma, 3 had previously received chemotherapy. This
may have affected the presence of circulating tumor
DNA and highlights the importance of sample homo-
geneity in this type of study and that ideally samples
should be extracted prior to starting treatment.
In general the frequency of CTC detection was very
low in PDAC cases as compared to other solid tu-
mors such as colorectal cancer where CTC have been
detected in 36 % of patients with stage I-IV disease
[20] with the CellSearch® system. In addition, the
number of CTC detected was very low, we detected a
range of 1–13 CTC in patients with metastatic dis-
ease as compared to other studies in colorectal cancer
where 29 % of patients with stage IV have 3 CTC or
more [21], and metastatic prostate and breast cancer
where 57 % and 25 % of patients had 5 CTC or more
respectively [8, 22]. CTC were most frequently de-
tected in metastatic patients, and one CTC was de-
tected in a patient with resectable disease which falls
within the limit of false positive data.
The low detection rate may be due to physiological
reasons, such as the fact that pancreatic tumors are gen-
erally poorly vascularised and the disease is more local-
ized with metastasis mainly in the liver and peritoneum
[23]. However, the low detection rate may also be due to
the detection method. The CellSearch® system is based
on the detection of cells that express the epithelial
markers EpCAM and cytokeratin (CK), thus cells that
do not express these antigens will not be detected by
this approach. We have shown that cultured cells origin-
ating from a pancreatic tumor are successfully identified
by the system; however these are adherent cultured cells
and thus are likely to express EpCAM at high levels.
EpCAM is expressed in many epithelial tumors and thus
is a widely used tumor marker. A recent study in a
mouse model of PDAC demonstrated that the pheno-
type of pancreatic circulating epithelial cells is very
heterogeneous and only 27 % express EpCAM whereas
40 % express the mesenchymal marker Zeb1 [24]. CTC
expressing both epithelial and mesenchymal markers,
have been identified in patients with breast and non-
small cell lung cancer [25] suggesting that CTC may
undergo an epithelial to mesenchymal transition
(EMT) and thus exhibit reduced expression of epithe-
lial markers such EpCAM and CK.
These results led us to investigate other methods for
the detection of CTC in pancreatic cancer via a marker
independent approach. We have shown that negative
selection of CD45 expressing cells is a feasible strategy
to enrich the CTC population from whole blood. We
have demonstrated that patients negative for CTC using
the CellSearch® System were positive for a KRAS mu-
tation in CD45 depleted blood indicating that (1)
CTC exist in peripheral blood and (2) that there are
a sufficient number of cells for detection using this
low sensitivity approach, but there is an obvious need
to apply the appropriate makers for their detection.
The fact that patients positive for a KRAS mutation in
CD45 depleted blood were negative for a KRAS muta-
tion in plasma indicates that the majority of cfDNA is
unlikely to come from CTC. This is consistent with pre-
vious findings that patients with digestive cancers with
detectable cftDNA (circulating free tumor DNA) are not
necessarily CTC positive [26].
This pilot study demonstrates that patient’s positive
for CTC or KRAS mutations in plasma have a statis-
tically significant poorer overall survival. The liquid
biopsy for CTC and cftDNA detection are promising
minimally invasive biomarkers in the PDAC setting.
However, in order to explore the viability of CTC and
cftDNA as prognostic and predictive biomarkers in
PDAC we would require serial samples taken during
the course of the disease from PDAC cases.
Conclusions
 KRAS mutant circulating free DNA is a promising
marker for the management of patients with PDAC
of all stages.
 The concentration of cfDNA may act as a surrogate
marker of disease stage, however this needs to be
studied in a larger patient cohort.
 CTC detection using the CellSearch® system as a
marker in pancreatic cancer is limited due to the
low detection rate and the fact that they are
usually found in patients with a metastatic disease
when treatment options are more limited.
 The CellSearch® system may not be adequate
for the detection of CTC in the context of
pancreatic cancer. In general the detection of
CTC in PDAC is hindered by a lack of data
with regard to the phenotype of these cells
thus it is difficult to select adequate markers
for their detection.
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